Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{187222,
        author = {Sunil Baban Rathod and Anjali Gahininath Kekan and Miss.Reshma Dilip Pawar and Payal Subhash Ghode},
        title = {Parkinson's Disease: Bridging Gaps, Building Biomarkers and Reimagining Clinical Translation},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {4947-4958},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=187222},
        abstract = {Parkinson's disease (PD) represents one of the most challenging neurodegenerative disorders, characterized by progressive motor and non-motor symptoms that significantly impact quality of life. Despite decades of research, substantial gaps remain in early diagnosis, disease monitoring, and therapeutic development. This review examines the current landscape of PD biomarker research, highlighting advances in fluid-based, imaging, and digital biomarkers, while addressing the translational challenges that impede their clinical implementation. We discuss emerging technologies, including alpha-synuclein seed amplification assays, neuroimaging innovations, and multi-modal biomarker approaches that promise to revolutionize PD diagnosis and treatment. Furthermore, we explore the critical barriers to clinical translation and propose frameworks for accelerating the path from bench to bedside, emphasizing the need for standardization, validation, and patient-centered approaches in biomarker development.},
        keywords = {Parkinson's disease, biomarkers, alpha-synuclein, neuroimaging, clinical translation, precision medicine},
        month = {November},
        }